Ainos, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chun-Hsien Tsai
- Full Time Employees
- 41
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3050 Post Oak Boulevard Houston TX United States of America 77056
- IPO Date
- Jan 8, 2021
- CIK
- 0001014763
- Website
- ainos.com
- Similar Companies
- Business
- Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company that pioneers SmellTech, AI diagnostics, and immune therapeutics; its proprietary AI Nose platform and smell language model (SLM) digitize scents into machine-readable Smell IDs for applications in robotics, smart factories, senior care, semiconductor manufacturing, women's health, and environmental monitoring; the company also develops VELDONA, a low-dose oral interferon targeting rare diseases, autoimmune disorders including primary Sjögren's syndrome and HIV-related oral warts, infectious diseases, and animal health applications such as feline chronic gingivostomatitis. Ainos offers AI Nose hardware and software including patented devices for industrial and healthcare use, VOC point-of-care tests like Ainos Flora for vaginal health and STIs, Ainos Pen portable breath analyzer, and CHS430 for ventilator-associated pneumonia; its biotech portfolio encompasses VELDONA human and pet therapeutics, synthetic RNA technologies, and telehealth-friendly POCT solutions. Founded in 1984 and headquartered in San Diego, California, the company--formerly Amarillo Biosciences, Inc. until its name change in May 2021--operates globally with a focus on the United States, Taiwan, Japan, and Southeast Asia. In recent developments, Ainos reported third-quarter 2025 financial results highlighting expansion of industrial partnerships to six, including a September 2025 distribution agreement with Topco Scientific across the U.S., Taiwan, Japan, and Southeast Asia, and an October 2025 strategic alliance with NEXCOM for integrating AI Nose into industrial edge computing; the company secured a $2.1 million commercial order from ASE Technology in August 2025 for AI Nose deployment in semiconductor manufacturing, debuted its patented AI Nose device in August 2025 targeting SmellTech-as-a-Service subscriptions, and showcased the technology at COMPUTEX 2025 and Automation Taipei 2025 with partners ugo and Kenmec; additionally, Ainos received Taiwan Food and Drug Administration approval in August 2025 for a VELDONA clinical study in primary Sjögren's syndrome starting October 2025, with prior TFDA and IRB clearances for HIV oral warts trials, alongside a GICS reclassification to Technology Hardware, Storage & Peripherals in October 2025.
Company News
Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment
Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract
Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence
Ainos, Inc. (NASDAQ:AIMD) Shares Shorted: Short Interest Up 172.6% in September
Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework
VASRO Research Highlights Ainos' New Order, Semiconductor Commercial Momentum and 1 Billion+ Chemical Dataset
Ainos Advances AI Nose into Commercial Deployment in Front-End Semiconductor Manufacturing
Ainos Secures Three Japanese Robotics Patents, Advancing Chemical Perception for the Physical AI Era
Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management
Ainos Unveils Next-Generation AI Nose, Advancing the Infrastructure for Chemical Intelligence
Ainos Surpasses 878 Million Real-World Data Points, Up 43% in 23 Days as 1,400-System AI Nose Semiconductor Deployment Advances
Ainos to Showcase Environmental Intelligence for Physical AI at SEMICON Taiwan 2026
VASRO Research Highlights Ainos' Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset
Zacks Small-Cap Research Covers Ainos' AI Nose Platform and Expansion of Smell AI Applications
Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets
Ainos Expands Smell AI With Growing Real-World Scent Dataset for Physical AI
VASRO Research Highlights Ainos' Expansion of Smell AI Into Patient-Level Breath Intelligence
Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program
Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations